OraSure Technologies, Inc.

OraSure Technologies, Inc. is a Bethlehem, Pennsylvania-based medical device company specializing in the development, manufacture, and distribution of diagnostic products and sample management solutions. The company's core mission is to improve access, quality, and value of healthcare through innovative, effortless rapid tests and sample management solutions, aiming to decentralize diagnostics and connect people to vital health information wherever they are.

OraSure's product portfolio includes a range of non-invasive, point-of-need diagnostic tests, notably the OraQuick line for rapid detection of HIV, Hepatitis C, Ebola, and COVID-19. The company also provides oral fluid sample collection devices, such as the OraSure HIV-1 Oral Specimen Collection Device, and solutions for drug of abuse testing like the Intercept Oral Fluid Drug Test. Through its subsidiaries, including DNA Genotek and Sherlock Biosciences, OraSure offers molecular sample collection and stabilization products, supporting genomics research, diagnostics laboratories, and direct-to-consumer applications. These products are sold globally to clinical laboratories, hospitals, public health organizations, and directly to consumers.

Led by President and CEO Carrie Eglinton Manner, appointed in June 2022, OraSure Technologies is actively pursuing strategic growth initiatives. Recent developments include the acquisition of Sherlock Biosciences in December 2024, expanding its molecular diagnostics capabilities, and the submission of a rapid molecular CT/NG self-test and an at-home urine collection device for STIs to the FDA in late 2025. The company is navigating a transition away from pandemic-era revenues by focusing on its core diagnostic and sample management offerings, aiming for sustained innovation and market leadership in decentralized healthcare.